UK Community Advisory Board (UK-CAB)

UK-CAB 58: HIV and hormonal therapy

Friday 29 April 2016


09.30-09.45 Arrival
09.45-10.00 Welcome and introductions, UK-CAB updates
10.00-10.45 HIV and menopause – Shema Tariq
10.45-11.15 Community engagement on BHIVA guidelines – Robert James
11.15-11.30 BREAK
11.30-12.30 Personal experience: Trans*woman – Catalina Hermes
12.30-14.00 LUNCH
14.00-15.30 Community response to NHS PrEP reconsideration –NATAgeing conference feedback – Damian Kelly
15.30-15.40 BREAK
15.40-16.15 Study discussion: Linkage to care following HIV diagnosis – Sarah Croxford, UCL
Conferences feedback: BHIVA -Dano Wheals, CROI
16.15-16.45 Member updates 
Stigma index – Alastair Hudson,
London Combined Audit &Outcomes and Drug & Treatment Sub Group – Virginia Cucchi
16.45 AOB, meeting close

Presentations from this meeting

The menopause and women living with HIV
PrEP update from NAT
Ageing with HIV conference feedback
Linkage to care following an HIV diagnosis
Stigma index 2015 survey results

Background reading

NHS Choices website about Menopause
Prime Study website –  Major study into menopause and HIV at UCL.
HIV and menopause (Shema Tariq)

HIV and Vulnerable Populations: Transgender Medicine (Anita Radix) (PowerPoint from BHIVA Annual Conference 2015)
A Trans Man Discusses PrEP and Condomless Casual Sex

HIV i-Base questions about trans issues inc. drug interactions, and surgery

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.